Range of qualified clients: CDEC reviewed the uncertainty in the number of patients with reasonably significant to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some clients that are categorized as possessing gentle or moderate illness can have a intense bleeding phenotype, https://hemgenix04837.ka-blogs.com/89253115/examine-this-report-on-hemgenix